Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
AAC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Stroke 33:2337-2341, Pasternak,R.C.,et al, 2002
The Therapeutic Dilemma of Inclusion Body Myositis
Neurol 48:567-568, Barohn,R.J., 1997
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Common Variable Immunodeficiency and Inclusion Body Myositis:A Distinct Myopathy Mediated by Natural Killer Cells
Ann Neurol 37:806-810, Dalakas,M.C.&Illa,I., 1995
Treatment of Inclusion-Body Myositis with High-Dose Intravenous Immunoglobulin
Neurol 43:876-879, Soueidan,S.A.&Dalakas,M.C., 1993
Pyomyositis in Patients with the Human Immunodeficiency Virus:An Unusual Form of Disseminated Bacterial Infection
Am J Med 91:129-136, Widrow,C.A.,et al, 1991
Myopathy & Hypersensitivity to Phenytoin
Neurol 33:790-791, Harney,J.,et al, 1983
Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972